A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants

NCT05644353 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Mirikizumab

Sponsor

Eli Lilly and Company